

IMTEC-VASCULITIS-LIA

Vasculitis LIA

Line Immuno Assay (LIA) for the Detection of Antibodies in Autoimmune Vasculitis (PR3, MPO and GBM)

Package Size

REF	ITC82040	24 Tests	Complete Testkit
IVD			

Please read the instructions carefully before testing

Intended Use

IMTEC-Vasculitis-LIA is an indirect membrane based enzyme immunoassay (LIA) for the qualitative measurement of IgG class antibodies against PR3, MPO and GBM in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of systemic vasculitis, i.e. Wegener's granulomatosis, and the Goodpasture syndrome.

Proteinase 3 (PR3) is the main target of cytoplasmic anti-neutrophil cytoplasm antibodies (cANCA). In contrast to that, perinuclear ANCA (pANCA) mainly react with myeloperoxidase (MPO).

cANCA are closely related to Wegener's granulomatosis classically causing severe glomerulonephritis. Repeated examination for cANCA is therefore of value for monitoring of disease activity and effect of treatment.

pANCA, detected by indirect immunofluorescence, can also be found in a lot of diseases apart from vasculitis. Consequently the detection of cANCA and pANCA by indirect immune fluorescence is not sufficient to proof systemic necrotising vasculitis. Therefore it is necessary to analyze the „fine specification“ of PR3-ANCA and MPO-ANCA by ELISA as a second step or in parallel.

Anti-GBM antibodies (anti-glomerular basement membrane antibodies) can be detected in about 90% of patients with Goodpasture's syndrome. While Goodpasture's syndrome is a relatively rare condition (0.5% of all patients with renal diseases), it is rapidly progressive and, if not treated, fatal in 75-90%. An early diagnosis and an immediate and correct treatment decrease the lethality dramatically.

Principle

The test is based on the principle of the line immuno assay (LIA). The antigens are applied as lines on a nitrocellulose membrane:

antigens	identity
PR3	native
MPO	native
GBM	native

The nitrocellulose membrane is blocked to prevent unspecific reactions. During incubation of a strip with diluted patient samples autoantibodies present in the sample will bind to the antigens on the strip. For the detection of the bound antibodies a secondary horseradish peroxidase (HRP)-labelled anti-human IgG antibody is used. After addition of the substrate and stop solution the appearance of brown lines indicate the existence of (auto) antibodies against the respective antigen.

Kit Content

STRIP	24	Test Strips (purple colour coding) coated with antigen (see table), ready for use
DIL LIA	3 Bottles	Powder for the preparation of 30 ml dilution buffer (blue cap)
WASH 20x WB03	50 ml	Washing Buffer (black cap) concentrate (20x) for 1 l buffer
CON	29 ml	Conjugate Solution (white cap) anti-human-IgG conjugate, ready for use
SUB LIA	30 ml	Substrate Solution (black cap), ready for use colourless to bluish 3,3', 5,5'-tetramethylbenzidin 1.2 mmol/l hydrogen peroxide 2.4 mmol/l
STOP LIA	26 ml	Stop Solution (red cap) sulphuric acid, ready for use 0.1 mol/l
	2 pcs.	Incubation Tray
	1 pc. each	Scoring sheet, Tweezers, bonding sheet, transparent Evaluation Template

Safety Notes

Do not swallow the reagents. Avoid contact with eyes, skin and mucous membranes. All patient specimens should be handled as potentially infectious. Wear protective clothing and disposable gloves according to Good Laboratory Practices.

All materials contaminated with patient specimens should be inactivated by validated procedures (autoclaving or chemical treatment) in accordance with applicable regulations.

Stability

When stored at 2...8°C unopened vials are stable until the expiry date.

After reconstitution, **DIL LIA** and **WASH** and opened **CON** are stable for 6 weeks at 2...8°C.

Store **SUB LIA** protected from light.

Precautions

DIL LIA, **WASH|20x** WB03 and **SUB LIA** may be interchanged between lots and LIA test kits that share the same reagent designation.

All other reagents are specific for the individual test kit lot and must not be interchanged with other lots and test kits.

Do not use polystyrene vessels for handling of **CON**.

Any crystallised salt of **WASH|20x** inside the bottle must be resolved before use.

Do not dry **STRIP** during the incubation steps.

Do not touch **STRIP** with fingers, use tweezers.

Remove diluted samples completely after incubation of **STRIP** to avoid cross contamination.

Use rocking shaker during all incubation steps.

Specimen, Controls

Serum and plasma with the anticoagulants citrate or EDTA.

Do not use highly lipemic, hemolysed or icteric specimens.

Undiluted specimens may be stored for 5 days at 2...8°C, or for one year at -20°C. **Freeze and thaw once only.** Thawed specimen should be carefully homogenised. Eliminate particulate matter by centrifugation or filtration.

Reagent preparation

Bring all reagents to room temperature (15...25°C) before use.

Reagents not in use should always be stored at 2...8°C.

Washing Buffer Solution **WASH**

Dilute 1 part **WASH|20x** with 19 parts distilled water.

Dilution buffer Solution **DIL LIA**

Dissolve the content of one bottle **DIL LIA** with 30 ml of **WASH** and agitate well.

Procedure

Wash Procedure

The wash procedure is critical. Insufficient washing will result in poor precision or falsely high band intensity.

W1: Remove liquids completely.

W2: Add **WASH** and incubate for 5 min with gentle agitation.

W3: After washing, remove remaining liquid.

Pipetting Scheme

Follow the procedure exactly as described. Pay particular attention to the washing procedure!

⚠ Reagents and specimens should be at room temperature before use.

⚠ Use rocking shaker during all incubation steps.

Sample Preparation:

Dilute specimen 1:101 with reconstituted **[DIL|LIA]**

(10 µl serum + 1 ml **[DIL|LIA]**)

1 ml is needed for each well.

Step 1	Well [ml]
Insert [STRIP] into the incubation tray colour coding facing up	--
[WASH] to wet the membrane	1
Incubate 1 min. at room temperature	
Remove [WASH]	
Step 2	
Diluted samples	1
Incubate 30 min. at room temperature	
Wash 3 times as described (see W1 - W3)	
[WASH]	1
Step 3	
[CON]	1
Incubate 30 min. at room temperature	
Wash 3 times as described (see W1 - W3)	
[WASH]	1
Step 4	
[SUB LIA]	1
Incubate 10 min. at room temperature	
Remove [SUB LIA]	
Step 5	
Add distilled water	1
Incubate 1 min. at room temperature	
Remove distilled water	
[STOP LIA]	1
Incubate 5 min. at room temperature	
Remove [STOP LIA]	
Dry [STRIP] thoroughly	

Automation

The IMTEC-Vasculitis-LIA may be processed with suitable automated Blot analyzers. Applications have to be validated in prior to diagnostic use.

For automated interpretation of LIA strips use HumaScan (**[REF]** ITC02851).

Validation of the Test

The test results are valid provided the following criteria are met for each **[STRIP]**:

- Function control is visible.
- Cut-off control is visible.
- Intensity function control > intensity cut-off control

Interpretation of Results

Fix **[STRIP]** onto scoring sheet and align the reference line of the **[STRIP]** with the reference line on the scoring sheet.

Align the dotted reference line of the evaluation template with the reference line of the **[STRIP]**.

The interpretation of the test results takes place exclusively on basis of the respective cut-off control regarded for each **[STRIP]**:

The test result is **negative**, if no band is to be recognised or if the band exhibits a smaller intensity in comparison to the cut-off control.

The test is **equivocal**, if the intensity of the band and the intensity of the cut-off control do not significantly differ. In the case of an equivocal result the test should be repeated with a new sample.

The test result is **positive**, if a band exhibits a stronger staining in comparison to the cut-off control.

Record the respective test results on the scoring sheet.

Limitations

A positive result must be used in association with clinical evaluation and diagnostic procedures. The values obtained from this assay are intended to be an aid for diagnosis only.

The intensity of the band colour does not necessarily correlate with antibody titres as obtained with other reference methodologies. Samples from apparent normal blood donors may contain autoantibodies.

If the patient sample contains elevated levels of immune complexes or other immunoglobulin aggregates, false positive results by non-specific binding cannot be ruled out.

Performance Characteristics

Typical performance data can be found in the Verification Report, accessible via:

www.human.de/data/gb/vr/la-82040.pdf or

www.human-de.com/data/gb/vr/la-82040.pdf

If the performance data are not accessible via internet, they can be obtained free of charge from your local distributor.

Note

The handling should always be in compliance with common GLP requirements (*)! The validation criteria must be met!

(*This includes: Proper caps being replaced on the vials and firmly tightened / Remove only reagents required for a run from stock solutions if they could come into contact with other contaminating solutions like patient specimens etc. / Stock solutions always returned to 2...8°C when not in use.)

Colour coding

The colour coding attached above the reference serves the identification of the available IMTEC-LIA-tests.

Safety Notes

[STOP] Warning!

• Hazard statements

H315 Causes skin irritation.

H319 Causes serious eye irritation.

• Precautionary statements

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P321 Specific treatment (see on this label).

P362 Take off contaminated clothing and wash before reuse.

P332+P313 If skin irritation occurs: Get medical advice/attention.

References

1. Conrad K. *et al.*, Autoantibodies in Systemic Autoimmune Diseases – A Diagnostic Reference; Pabst Science Publishers, Lengerich, 2008
2. Hellmark T. *et al.*, Kidney Int. **46**, 823-829 (1994).

LA-82040

INF ITC82040 GB

06-2015-16M



Human